Jose L. Sanchez-Vique

Mexicali, BCN 21000, Mexico

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 21 publications

Nrf2 Is Associated with Metastasis-Related Processes in a Chemoresistant Breast Cancer Model: Insights from siRNA Modulation.

Nrf2 Is Associated with Metastasis-Related Processes in a Chemoresistant Breast Cancer Model: Insights from siRNA Modulation.

Journal: International journal of molecular sciences

Published: February 07, 2026

Itopride as a Potential Drug Against Cancer (Breast and Prostate), by Repurposing Determined Through AI.

Itopride as a Potential Drug Against Cancer (Breast and Prostate), by Repurposing Determined Through AI.

Journal: Archiv der Pharmazie

Published: January 04, 2026

The transition from preclinical to clinical obesity: the importance of a borderline stage.

The transition from preclinical to clinical obesity: the importance of a borderline stage.

Journal: Clinical science (London, England : 1979)

Published: April 21, 2025

The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model.

The translation factor eIF4E is a key mediator of doxorubicin resistance: insights from a triple-negative breast cancer model.

Journal: Scientific reports

Published: February 28, 2025

Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

Lapatinib-Resistant HER2+ Breast Cancer Cells Are Associated with Dysregulation of MAPK and p70S6K/PDCD4 Pathways and Calcium Management, Influence of Cryptotanshinone.

Journal: International journal of molecular sciences

Published: February 23, 2025

Potential Ligands to Resistin Against Prostate Cancer, Evaluated by Molecular Docking and In Vitro Assays to Develop an Anticancer Drug.

Potential Ligands to Resistin Against Prostate Cancer, Evaluated by Molecular Docking and In Vitro Assays to Develop an Anticancer Drug.

Journal: Chemistry & biodiversity

Published: January 15, 2025

Screening of Leptin-LepR modulators using molecular docking and binding assay.

Screening of Leptin-LepR modulators using molecular docking and binding assay.

Journal: Bioinformation

Published: May 01, 2024

Potential Otubain1 Inhibitor, an Approach for a Treatment against Breast Cancer.

Potential Otubain1 Inhibitor, an Approach for a Treatment against Breast Cancer.

Journal: International journal of molecular and cellular medicine

Published: January 01, 2024

γ-Secretase Inhibitors Selected by Molecular Docking, to Develop a New Drug Against Alzheimer's Disease.

γ-Secretase Inhibitors Selected by Molecular Docking, to Develop a New Drug Against Alzheimer's Disease.

Journal: Reports of biochemistry & molecular biology

Published: August 09, 2023

Potential Inhibitors of The OTUB1 Catalytic Site to Develop an Anti-Cancer Drug Using In-Silico Approaches.

Potential Inhibitors of The OTUB1 Catalytic Site to Develop an Anti-Cancer Drug Using In-Silico Approaches.

Journal: Reports of biochemistry & molecular biology

Published: March 17, 2022

Synergistic effect of compounds directed to triosephosphate isomerase, a combination to develop drug against trichomoniasis.

Synergistic effect of compounds directed to triosephosphate isomerase, a combination to develop drug against trichomoniasis.

Journal: Archiv der Pharmazie

Published: January 27, 2022

AXL inhibitors selected by molecular docking: Option for reducing SARS-CoV-2 entry into cells.

AXL inhibitors selected by molecular docking: Option for reducing SARS-CoV-2 entry into cells.

Journal: Acta pharmaceutica (Zagreb, Croatia)

Published: October 18, 2021

Showing 1-12 of 21

Last Updated: 09/26/2026